What Alto Neuroscience Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 3 | 3 |
| Total trades | 7 | 10 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 189,886 | 189,886 |
| Disposed | 134,886 | 543,919 |
| Net activity | +55,000 | −354,033 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Smith Nicholas Conrad | PRESIDENT AND CFO | Oct 02 | Exercise / conversion · M | +55,000 | $2.32 | +$128K | 79,060 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 30 | Open-market sale · S | −886 | $26.87 | −$23.8K | 24,060 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 30 | Open-market sale · S | −23,170 | $25.78 | −$597K | 24,946 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 30 | Exercise / conversion · M | +24,056 | $2.35 | +$56.5K | 48,116 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 29 | Open-market sale · S | −110,830 | $26.58 | −$2.95M | 24,060 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 29 | Exercise / conversion · M | +54,375 | $2.35 | +$128K | 134,890 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 29 | Exercise / conversion · M | +56,455 | $2.35 | +$133K | 80,515 |
| Etkin Amit | PRESIDENT AND CEO | May 14 | Gift · G | −400,000 | — | — | 833,949 |
| Etkin Amit | PRESIDENT AND CEO | Mar 01 | Withheld — tax / exercise cost · F | −6,227 | $19.69 | −$123K | 1,233,949 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER & CBO | Mar 01 | Withheld — tax / exercise cost · F | −2,806 | $19.69 | −$55.3K | 24,060 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Jul 10 | Open-market buy · P | +2,931 | $13.22 | +$38.7K | 39,851 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Jul 09 | Open-market buy · P | +1,388 | $13.15 | +$18.3K | 36,920 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Jul 09 | Open-market buy · P | +10,681 | $12.53 | +$134K | 35,532 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | Mar 28 | Open-market buy · P | +4,550 | $16.56 | +$75.3K | 26,866 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | Mar 28 | Open-market buy · P | +1,600 | $15.80 | +$25.3K | 22,316 |
| Etkin Amit | PRESIDENT AND CEO | Mar 01 | Grant / award · A | +34,711 | — | — | 1,240,176 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | Mar 01 | Grant / award · A | +19,153 | — | — | 20,716 |
| Etkin Amit | PRESIDENT AND CEO | Feb 06 | Open-market buy · P | +3,125 | $16.00 | +$50K | 1,205,465 |
| Etkin Amit | PRESIDENT AND CEO | Feb 06 | Derivative Conversion · C | +11,777 | — | — | 1,202,340 |
| Cox Christopher Nixon | Director | Feb 06 | Derivative Conversion · C | +126,755 | — | — | 715,653 |
Loading...
